Differences in mean number of papers (top) and co-authors (bottom) depending on (1) NI membership and (2) time joined NI. by William C. Barley (8915282)

Subjects:

Regression estimates and incidence rate ratios from GLMER for number of papers (top) and coauthors (bottom). by William C. Barley (8915282)

Subjects:

Larger example of stimuli with cue relevant for Task 3. by Marcel F. Hinss (14675457)

Summary map of all contacts with statistically significant SVM classifications. by Alexander P. Rockhill (6053618)

“…<p>The top row presents the proportion of significant SVM clusters. It illustrates what proportions of channels are significant at that time-frequency ranging from 0 to 1. …”

Negative ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). by Peng-fei Han (694841)

Positive ion mode significant differential metabolites (Fold Change greater than 2 or less than 0.5). by Peng-fei Han (694841)

Change in Watt’s Connectedness Scale, Subscales by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Primary and secondary efficacy end points (intention-to-treat population). by Benjamin R. Lewis (22279166)

Subjects:

Demographic and clinical characteristics of participants at baseline. by Benjamin R. Lewis (22279166)

Subjects:

Study-related adverse events. by Benjamin R. Lewis (22279166)

Subjects:

Study flow chart. by Benjamin R. Lewis (22279166)

Subjects:

Change in QIDS-SR-16 and MBI-HSS-MP by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Study CONSORT diagram. by Benjamin R. Lewis (22279166)

Subjects:

Change in Demoralization Scale (DSII) by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Change in Watt’s Connectedness Scale (WCS), General Connectedness by Treatment Group. by Benjamin R. Lewis (22279166)

Subjects:

Sobel test for the significance of the mediation effect. by Getachew Magnar Kitila (19935139)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

“…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…”

Scheme of g-λ model with larger values λ. by Zhanfeng Fan (20390992)

“…The findings suggest that when λ is respectively equal to 4.19, 8.57, 10, and 12.15, the peak particle velocity (PPV) of the transmitted waves is significantly close to the incident wave amplitude. Furthermore, when λ is fixed, the energy transmission coefficient increases with the incident wave amplitude but decreases with the incident wave frequency. …”